MTOR and renal cell carcinoma: Inhibitors of the mTOR pathway have in fact shown clear benefits in some cancers such as Mantle Cell Lymphomas, Renal Cell Carcinoma and Tuberous Sclerosis Complex-related tumors but have limited efficacy as single agents in most other cancers [14].